
    
      Study drug will be supplied as capsules and will be orally administered once daily for a
      total of 21 days. Eligible subjects will be admitted to an inpatient study unit on Day -6
      (six days before the first dose of study drug is administered) and will remain confined to
      the inpatient study unit throughout the dosing phase. Safety assessments, PK sampling, and
      cognitive testing will be performed.
    
  